Page last updated: 2024-11-09

monastrol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

monastrol: stops mitosis by fostering formation of monopolar spindles; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

(S)-monastrol : An ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate that has S configuration. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

monastrol : A racemate comprising equimolar amounts of R- and S-monastrol. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate : A member of the class of thioureas that is 3,4-dihydropyrimidine-2(1)-thione substituted by a 3-hydroxyphenyl group at position 4, an ethoxycarbonyl group at position 5, and a methyl group at position 6. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID2987927
CHEBI ID75382
CHEBI ID143544
SCHEMBL ID3168349
MeSH IDM0350330

Synonyms (106)

Synonym
CBDIVE_015834
HMS3267N03
BRD-A78377521-001-02-2
UPCMLD0ENAT5762435:001
monastrol
nsc-716782
NCI60_040353
PROBES2_000257
BSPBIO_001273
BIO1_001437
BIO2_000947
BIO1_000459
NCGC00025103-01
BIO2_000467
BIO1_000948
IDI1_002222
LOPAC0_000821
SMP1_000197
OPREA1_487786
254753-54-3
ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
monastrol, >=98% (hplc), solid
nsc716782
PROBES1_000001
PROBES1_000042
(s)-monastrol
NCGC00025103-03
NCGC00025103-02
4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydro-4h-pyrimidin-5-carboxylic acid ethyl ester
c18h23no3s
KBIO3_001085
KBIOSS_000613
KBIO2_000613
KBIO2_003181
KBIOGR_000613
KBIO2_005749
KBIO3_001086
BCBCMAP01_000162
PROBES1_000312
PROBES2_000376
NCGC00025103-04
STK386781
M 8515
HMS1990O15
ZINC00297106
chebi:75382 ,
AKOS000295413
HMS1792O15
HMS1362O15
AKOS002264887
CHEBI:143544
ethyl 4-(3-hydroxyphenyl)-6-methyl-2-sulfanylidene-3,4-dihydro-1h-pyrimidine-5-carboxylate
rac-ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
ethyl 6-(3-hydroxyphenyl)-2-mercapto-4-methyl-1,6-dihydropyrimidine-5-carboxylate
F3284-6466 ,
FT-0631206
FT-0628969
S8439
AKOS016315550
GR-322
329689-23-8
AKOS016068396
SCHEMBL3168349
1,2,3,4-tetrahydro-4-(3-hydroxyphenyl)-6-methyl-2-thioxo-5-pyrimidinecarboxylic acid, ethyl ester
smr004703468
MLS006011746
HB2551
5-[[4-[(1-methylcyclohexyl)methoxy] phenyl]methyl]-2,4-thiazolidinedione
AC-33010
HMS3403O15
DTXSID10388124
SR-01000357662-2
sr-01000357662
SR-01000357662-1
bdbm175356
ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate (11)
HY-101071A
CS-6183
ethyl 4-(3-hydroxyphenyl)-6-methyl-2-sulfanylidene-1,2,3,4-tetrahydropyrimidine-5-carboxylate
LOBCDGHHHHGHFA-UHFFFAOYSA-N
ethyl 6-methyl-4-(3-hydroxyphenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylate
AS-74678
J-016007
( inverted exclamation marka)-monastrol
ethyl 4-(3-hydroxyphenyl)-6-methyl-2-thioxo-3,4-dihydro-1h-pyrimidine-5-carboxylate
ethyl 6-(3-hydroxyphenyl)-4-methyl-2-sulfanyl-1,6-dihydropyrimidine-5-carboxylate
BCP19385
BCP06757
Z57061994
HMS3676E20
HMS3412E20
Q6898425
BRD-A78377521-001-03-0
EN300-1266062
5-pyrimidinecarboxylic acid,1,2,3,4-tetrahydro-4-(3-hydroxyphenyl)-6-methyl-2-thioxo-, ethyl ester
CCG-267397
(+/-)-monastrol
mfcd06762956
EX-A1988
dl-monastrol
D84039
EX-A4169
()-monastrol
A902103
6-methyl-4-(3-hydroxyphenyl)-2-thioxo-1,2,3,4-tetrahydropyrimidine-5-carboxylic acid ethyl ester
DTXSID501317756

Research Excerpts

Overview

Monastrol is a small, cell-permeable molecule that arrests cells in mitosis by specifically inhibiting Eg5, a member of the Kinesin-5 family. Monastrol exhibits an antiproliferative effect against several cell lines.

ExcerptReferenceRelevance
"Monastrol is a small cell-permeable heterocyclic molecule that is recognized as an inhibitor of mitotic kinesin Eg5. "( Synthesis and antitumoral activity of novel analogues monastrol-fatty acids against glioma cells.
Brinkerhoff, RC; De Oliveira, FS; De Oliveira, PM; Farias, LM; Horn, AP; Hort, MA; Marinho, MAG; Montes D'Oca, CR; Montes D'Oca, MG; Russowsky, D; Sobrinho, RCMA; Treptow, TM, 2018
)
2.17
"Monastrol is an allosteric inhibitor of the mitotic kinesin Eg5 that exhibits an antiproliferative effect against several cell lines. "( Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells.
D'Epiro, GF; de Fátima, Â; Mantovani, MS; Marques, LA; Niwa, AM; Ribeiro, LR; Sartori, D; Semprebon, SC, 2016
)
2.17
"Monastrol is a reversible, cell-permeable, non-tubulin interacting inhibitor of the mitotic kinesin Eg5 motor protein which is required for assembling and maintaining the mitotic spindle."( Transient exposure to the Eg5 kinesin inhibitor monastrol leads to syntelic orientation of chromosomes and aneuploidy in mouse oocytes.
Fuseler, JW; Mailhes, JB; Mastromatteo, C, 2004
)
1.3
"Monastrol is a small, cell-permeable molecule that arrests cells in mitosis by specifically inhibiting Eg5, a member of the Kinesin-5 family. "( Monastrol inhibition of the mitotic kinesin Eg5.
Cochran, JC; Gatial, JE; Gilbert, SP; Kapoor, TM, 2005
)
3.21
"Monastrol is a small molecule inhibitor that is specific for Eg5, a member of the kinesin 5 family of mitotic motors. "( A pathway of structural changes produced by monastrol binding to Eg5.
Cheung, H; Friedman, JM; Juszczak, LJ; Maliga, Z; Rosenfeld, SS; Xing, J, 2006
)
2.04

Effects

ExcerptReferenceRelevance
"Monastrol has no inhibitory effect on the following members of the kinesin superfamily: MC5 (Drosophila melanogaster Ncd), HK379 (H."( Interaction of the mitotic inhibitor monastrol with human kinesin Eg5.
Blangy, A; Crevel, I; Cross, R; DeBonis, S; Ebel, C; Gans, P; Hackney, DD; Kozielski, F; Lebeau, L; Simorre, JP; Skoufias, DA; Wade, RH, 2003
)
1.31

Actions

Monastrol is known to cause mitotic arrest in cancer cells. It inhibited Rap1A prenylation (geranylgeranylation) in intracellular Leishmania, which resulted in blockade at G1 phase of the cell cycle.

ExcerptReferenceRelevance
"Monastrol, known to cause mitotic arrest in cancer cells, inhibited Rap1A prenylation (geranylgeranylation) in intracellular Leishmania, which resulted in blockade at the G1 phase of the cell cycle."( A member of the Ras oncogene family, RAP1A, mediates antileishmanial activity of monastrol.
Chang, KP; Dutta, S; Kaur, J; Singh, N, 2013
)
1.34
"Monastrol appears to inhibit microtubule-stimulated ADP release from Eg5 but does not compete with microtubule binding, suggesting that monastrol binds a novel allosteric site in the motor domain."( Evidence that monastrol is an allosteric inhibitor of the mitotic kinesin Eg5.
Kapoor, TM; Maliga, Z; Mitchison, TJ, 2002
)
1.4
"Monastrol promotes a dramatic decrease in the observed rate of Eg5 association with microtubules, and ADP release is slowed without trapping the Mt.Eg5.ADP intermediate."( Monastrol inhibition of the mitotic kinesin Eg5.
Cochran, JC; Gatial, JE; Gilbert, SP; Kapoor, TM, 2005
)
2.49

Treatment

Monastrol treatment decreased cell viability only in MCF-7 tumor cells. Treatment with monastrol enhanced functional and histological recovery in experimental autoimmune neuritis.

ExcerptReferenceRelevance
"Monastrol-treated animals showed partially reinnervated or intact neuromuscular junctions."( Kinesin-5 inhibition improves neural regeneration in experimental autoimmune neuritis.
Ackfeld, R; Barham, M; Fink, GR; Hommen, F; Klein, I; Kohle, F; Lehmann, HC; Schneider, C; Svačina, MKR; Vilchez, D, 2023
)
1.63
"Monastrol treatment decreased cell viability only in MCF-7 tumor cells."( Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells.
D'Epiro, GF; de Fátima, Â; Mantovani, MS; Marques, LA; Niwa, AM; Ribeiro, LR; Sartori, D; Semprebon, SC, 2016
)
1.44
"Monastrol-treated Eg5 also shows a decreased relative affinity for microtubules under equilibrium conditions."( Monastrol inhibition of the mitotic kinesin Eg5.
Cochran, JC; Gatial, JE; Gilbert, SP; Kapoor, TM, 2005
)
2.49
"Monastrol treatment had no effect on developing zygotes prior to entry into mitosis. "( Kinesin-5 motors are required for organization of spindle microtubules in Silvetia compressa zygotes.
Kropf, DL; Peters, NT, 2006
)
1.78
"Treatment with monastrol enhanced functional and histological recovery in experimental autoimmune neuritis. "( Kinesin-5 inhibition improves neural regeneration in experimental autoimmune neuritis.
Ackfeld, R; Barham, M; Fink, GR; Hommen, F; Klein, I; Kohle, F; Lehmann, HC; Schneider, C; Svačina, MKR; Vilchez, D, 2023
)
1.26
"Treatment with monastrol induced in MCF-7 cells a 5-fold increase in the mRNA levels of the CDKN1A gene, an inhibitor of CDKs related with cell cycle arrest in response a stress stimulus, and a 2-fold decrease in CDKN1C mRNA levels in HB4a cells."( Antiproliferative activity of monastrol in human adenocarcinoma (MCF-7) and non-tumor (HB4a) breast cells.
D'Epiro, GF; de Fátima, Â; Mantovani, MS; Marques, LA; Niwa, AM; Ribeiro, LR; Sartori, D; Semprebon, SC, 2016
)
1.06

Toxicity

ExcerptReferenceRelevance
"Neurotoxicity is a relevant side effect of bortezomib treatment."( Kinesin-5 Blocker Monastrol Protects Against Bortezomib-Induced Peripheral Neurotoxicity.
Barham, M; Bobylev, I; Klein, I; Lehmann, HC; Neiss, WF; Peters, D; von Strandmann, EP; Vyas, M, 2017
)
0.79

Pharmacokinetics

ExcerptReferenceRelevance
" The present work investigated the pharmacokinetic and tissue distribution as well as acute toxicity of a new chemical entity (NCE), the anticancer candidate LaSOM 65 in Wistar rats."( Pre-clinical pharmacokinetics and acute toxicological evaluation of a monastrol derivative anticancer candidate LaSOM 65 in rats.
Azeredo, FJ; Canto, RF; Dalla Costa, T; Dallegrave, E; Eifler-Lima, VL; Haas, SE; Pigatto, MC; Torres, BG; Uchôa, Fde T, 2014
)
0.64

Compound-Compound Interactions

ExcerptReferenceRelevance
" Image-based profiling and analysis led to the rapid discovery of a drug combination effective against TNBC in vitro and in vivo, and has the potential to lead to the development of new therapeutic options in other hard-to-treat cancers."( Computational analysis of image-based drug profiling predicts synergistic drug combinations: applications in triple-negative breast cancer.
Beck, D; Brandl, MB; Kavallaris, M; Li, F; Pasquier, E; Wong, ST; Zhang, S; Zhao, H, 2014
)
0.4

Bioavailability

ExcerptReferenceRelevance
" The compound showed good bioavailability and linear pharmacokinetics after oral doses."( Pre-clinical pharmacokinetics and acute toxicological evaluation of a monastrol derivative anticancer candidate LaSOM 65 in rats.
Azeredo, FJ; Canto, RF; Dalla Costa, T; Dallegrave, E; Eifler-Lima, VL; Haas, SE; Pigatto, MC; Torres, BG; Uchôa, Fde T, 2014
)
0.64
" Further optimization of the pharmacokinetic (PK) properties afforded MK-8267 as a potent, orally bioavailable and brain penetrant KSP inhibitor which showed anti-tumor activity in preclinical xenograft models."( Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
Allbritton, O; Angeles, AR; Basso, AD; Dai, C; Gray, K; Liang, L; Liu, M; Mansoor, UF; Siddiqui, MA; Tang, H; Vitharana, D; Yang, L, 2015
)
0.42
"The ATP-binding cassette transporter P-glycoprotein (P-gp) is known to limit both brain penetration and oral bioavailability of many chemotherapy drugs."( A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
Ambudkar, SV; Brimacombe, KR; Chen, L; Gottesman, MM; Guha, R; Hall, MD; Klumpp-Thomas, C; Lee, OW; Lee, TD; Lusvarghi, S; Robey, RW; Shen, M; Tebase, BG, 2019
)
0.51
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
antineoplastic agentA substance that inhibits or prevents the proliferation of neoplasms.
EC 3.5.1.5 (urease) inhibitorEC 3.5.1.* (non-peptide linear amide C-N hydrolase) inhibitor that interferes with the activity of urease (EC 3.5.1.5), reducing hydrolysis.
antileishmanial agentAn antiprotozoal drug used to treat or prevent infections caused by protozoan parasites that belong to the genus Leishmania.
antimitoticAny compound that inhibits cell division (mitosis).
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (5)

ClassDescription
racemateA racemate is an equimolar mixture of a pair of enantiomers.
enoate esterAn alpha,beta-unsaturated carboxylic ester of general formula R(1)R(2)C=CR(3)-C(=O)OR(4) (R(4) =/= H) in which the ester C=O function is conjugated to a C=C double bond at the alpha,beta position.
ethyl esterAny carboxylic ester resulting from the formal condensation of the carboxy group of a carboxylic acid with ethanol.
phenolsOrganic aromatic compounds having one or more hydroxy groups attached to a benzene or other arene ring.
thioureasCompounds of general formula RR'NC(=S)NR''R'''.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (34)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
15-lipoxygenase, partialHomo sapiens (human)Potency19.95260.012610.691788.5700AID887
Fumarate hydrataseHomo sapiens (human)Potency0.33170.00308.794948.0869AID1347053
TDP1 proteinHomo sapiens (human)Potency23.71500.000811.382244.6684AID686978
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency1.12200.011212.4002100.0000AID1030
EWS/FLI fusion proteinHomo sapiens (human)Potency0.11630.001310.157742.8575AID1259252; AID1259253; AID1259255; AID1259256
polyproteinZika virusPotency0.33170.00308.794948.0869AID1347053
cytochrome P450 2C19 precursorHomo sapiens (human)Potency25.11890.00255.840031.6228AID899
cytochrome P450 2C9 precursorHomo sapiens (human)Potency19.95260.00636.904339.8107AID883
15-hydroxyprostaglandin dehydrogenase [NAD(+)] isoform 1Homo sapiens (human)Potency19.95260.001815.663839.8107AID894
mitogen-activated protein kinase 1Homo sapiens (human)Potency25.11890.039816.784239.8107AID995
DNA polymerase kappa isoform 1Homo sapiens (human)Potency23.77810.031622.3146100.0000AID588579
cytochrome P450 3A4 isoform 1Homo sapiens (human)Potency1.00000.031610.279239.8107AID884; AID885
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency35.48130.251215.843239.8107AID504327
Gamma-aminobutyric acid receptor subunit piRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit deltaRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-5Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-4Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit gamma-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit alpha-6Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Histamine H2 receptorCavia porcellus (domestic guinea pig)Potency19.95260.00638.235039.8107AID883
Gamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-3Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
GABA theta subunitRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
Gamma-aminobutyric acid receptor subunit epsilonRattus norvegicus (Norway rat)Potency1.00001.000012.224831.6228AID885
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Aurora kinase AHomo sapiens (human)IC50 (µMol)50.00000.00000.46208.6000AID537125
UreaseCanavalia ensiformis (jack bean)Ki25.66000.40700.40700.4070AID1801532
Kinesin-like protein KIF11Homo sapiens (human)IC50 (µMol)12.82470.00011.405710.0000AID1610651; AID300454; AID300455; AID300459; AID537124; AID608381; AID614470; AID723809; AID740791
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (39)

Processvia Protein(s)Taxonomy
protein phosphorylationAurora kinase AHomo sapiens (human)
response to woundingAurora kinase AHomo sapiens (human)
liver regenerationAurora kinase AHomo sapiens (human)
G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
mitotic cell cycleAurora kinase AHomo sapiens (human)
chromatin remodelingAurora kinase AHomo sapiens (human)
protein phosphorylationAurora kinase AHomo sapiens (human)
apoptotic processAurora kinase AHomo sapiens (human)
spindle organizationAurora kinase AHomo sapiens (human)
spindle assembly involved in female meiosis IAurora kinase AHomo sapiens (human)
mitotic centrosome separationAurora kinase AHomo sapiens (human)
anterior/posterior axis specificationAurora kinase AHomo sapiens (human)
regulation of G2/M transition of mitotic cell cycleAurora kinase AHomo sapiens (human)
negative regulation of gene expressionAurora kinase AHomo sapiens (human)
peptidyl-serine phosphorylationAurora kinase AHomo sapiens (human)
regulation of protein stabilityAurora kinase AHomo sapiens (human)
negative regulation of protein bindingAurora kinase AHomo sapiens (human)
positive regulation of proteasomal ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
negative regulation of apoptotic processAurora kinase AHomo sapiens (human)
proteasome-mediated ubiquitin-dependent protein catabolic processAurora kinase AHomo sapiens (human)
positive regulation of mitotic nuclear divisionAurora kinase AHomo sapiens (human)
positive regulation of mitotic cell cycleAurora kinase AHomo sapiens (human)
regulation of centrosome cycleAurora kinase AHomo sapiens (human)
protein autophosphorylationAurora kinase AHomo sapiens (human)
cell divisionAurora kinase AHomo sapiens (human)
centrosome localizationAurora kinase AHomo sapiens (human)
cilium disassemblyAurora kinase AHomo sapiens (human)
protein localization to centrosomeAurora kinase AHomo sapiens (human)
positive regulation of mitochondrial fissionAurora kinase AHomo sapiens (human)
positive regulation of oocyte maturationAurora kinase AHomo sapiens (human)
regulation of signal transduction by p53 class mediatorAurora kinase AHomo sapiens (human)
neuron projection extensionAurora kinase AHomo sapiens (human)
mitotic spindle organizationAurora kinase AHomo sapiens (human)
regulation of cytokinesisAurora kinase AHomo sapiens (human)
mitotic cell cycleKinesin-like protein KIF11Homo sapiens (human)
microtubule-based movementKinesin-like protein KIF11Homo sapiens (human)
spindle organizationKinesin-like protein KIF11Homo sapiens (human)
mitotic spindle organizationKinesin-like protein KIF11Homo sapiens (human)
mitotic centrosome separationKinesin-like protein KIF11Homo sapiens (human)
regulation of mitotic centrosome separationKinesin-like protein KIF11Homo sapiens (human)
cell divisionKinesin-like protein KIF11Homo sapiens (human)
mitotic spindle assemblyKinesin-like protein KIF11Homo sapiens (human)
spindle elongationKinesin-like protein KIF11Homo sapiens (human)
mitotic sister chromatid segregationKinesin-like protein KIFC1Homo sapiens (human)
mitotic metaphase chromosome alignmentKinesin-like protein KIFC1Homo sapiens (human)
cell divisionKinesin-like protein KIFC1Homo sapiens (human)
mitotic spindle assemblyKinesin-like protein KIFC1Homo sapiens (human)
microtubule-based movementKinesin-like protein KIFC1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (15)

Processvia Protein(s)Taxonomy
protein kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine kinase activityAurora kinase AHomo sapiens (human)
protein serine/threonine/tyrosine kinase activityAurora kinase AHomo sapiens (human)
protein bindingAurora kinase AHomo sapiens (human)
ATP bindingAurora kinase AHomo sapiens (human)
protein kinase bindingAurora kinase AHomo sapiens (human)
ubiquitin protein ligase bindingAurora kinase AHomo sapiens (human)
histone H3S10 kinase activityAurora kinase AHomo sapiens (human)
protein heterodimerization activityAurora kinase AHomo sapiens (human)
protein serine kinase activityAurora kinase AHomo sapiens (human)
molecular function activator activityAurora kinase AHomo sapiens (human)
microtubule motor activityKinesin-like protein KIF11Homo sapiens (human)
protein bindingKinesin-like protein KIF11Homo sapiens (human)
ATP bindingKinesin-like protein KIF11Homo sapiens (human)
microtubule bindingKinesin-like protein KIF11Homo sapiens (human)
protein kinase bindingKinesin-like protein KIF11Homo sapiens (human)
plus-end-directed microtubule motor activityKinesin-like protein KIF11Homo sapiens (human)
microtubule motor activityKinesin-like protein KIFC1Homo sapiens (human)
ATP bindingKinesin-like protein KIFC1Homo sapiens (human)
ATP hydrolysis activityKinesin-like protein KIFC1Homo sapiens (human)
microtubule bindingKinesin-like protein KIFC1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (32)

Processvia Protein(s)Taxonomy
spindle microtubuleAurora kinase AHomo sapiens (human)
nucleusAurora kinase AHomo sapiens (human)
nucleoplasmAurora kinase AHomo sapiens (human)
centrosomeAurora kinase AHomo sapiens (human)
centrioleAurora kinase AHomo sapiens (human)
spindleAurora kinase AHomo sapiens (human)
cytosolAurora kinase AHomo sapiens (human)
postsynaptic densityAurora kinase AHomo sapiens (human)
microtubule cytoskeletonAurora kinase AHomo sapiens (human)
basolateral plasma membraneAurora kinase AHomo sapiens (human)
midbodyAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
ciliary basal bodyAurora kinase AHomo sapiens (human)
germinal vesicleAurora kinase AHomo sapiens (human)
axon hillockAurora kinase AHomo sapiens (human)
pronucleusAurora kinase AHomo sapiens (human)
perinuclear region of cytoplasmAurora kinase AHomo sapiens (human)
mitotic spindleAurora kinase AHomo sapiens (human)
meiotic spindleAurora kinase AHomo sapiens (human)
mitotic spindle poleAurora kinase AHomo sapiens (human)
glutamatergic synapseAurora kinase AHomo sapiens (human)
spindle pole centrosomeAurora kinase AHomo sapiens (human)
chromosome passenger complexAurora kinase AHomo sapiens (human)
spindle midzoneAurora kinase AHomo sapiens (human)
kinetochoreAurora kinase AHomo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit gamma-2Rattus norvegicus (Norway rat)
spindle poleKinesin-like protein KIF11Homo sapiens (human)
spindle microtubuleKinesin-like protein KIF11Homo sapiens (human)
spindleKinesin-like protein KIF11Homo sapiens (human)
cytosolKinesin-like protein KIF11Homo sapiens (human)
microtubuleKinesin-like protein KIF11Homo sapiens (human)
membraneKinesin-like protein KIF11Homo sapiens (human)
mitotic spindleKinesin-like protein KIF11Homo sapiens (human)
kinesin complexKinesin-like protein KIF11Homo sapiens (human)
protein-containing complexKinesin-like protein KIF11Homo sapiens (human)
nucleusKinesin-like protein KIF11Homo sapiens (human)
mitotic spindleKinesin-like protein KIF11Homo sapiens (human)
plasma membraneGamma-aminobutyric acid receptor subunit alpha-1Rattus norvegicus (Norway rat)
plasma membraneGamma-aminobutyric acid receptor subunit beta-2Rattus norvegicus (Norway rat)
early endosomeKinesin-like protein KIFC1Homo sapiens (human)
centrosomeKinesin-like protein KIFC1Homo sapiens (human)
membraneKinesin-like protein KIFC1Homo sapiens (human)
kinesin complexKinesin-like protein KIFC1Homo sapiens (human)
mitotic spindleKinesin-like protein KIFC1Homo sapiens (human)
microtubuleKinesin-like protein KIFC1Homo sapiens (human)
microtubule organizing centerKinesin-like protein KIFC1Homo sapiens (human)
nucleusKinesin-like protein KIFC1Homo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (231)

Assay IDTitleYearJournalArticle
AID512988Inhibition of recombinant Eg5-GFP in cell-free system assessed as Eg5 motility speed on microtubule at 100 uM by mean square displacement analysis in presence of 2 mM ATP (Rvb = 799+/-nm'2/s)2006Nature chemical biology, Sep, Volume: 2, Issue:9
Allosteric inhibition of kinesin-5 modulates its processive directional motility.
AID614357Growth inhibition of human RPMI8266 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID512993Inhibition of recombinant Eg5-GFP in cell-free system assessed as Eg5-GFP movement along microtubules without directionality at 100 uM by mean square displacement analysis in presence of 2 mM ADP2006Nature chemical biology, Sep, Volume: 2, Issue:9
Allosteric inhibition of kinesin-5 modulates its processive directional motility.
AID614395Growth inhibition of human KM12 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1377415Cell cycle arrest in human MOLT4 cells assessed as accumulation at G0/G1 phase at 0.43 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 74.22%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID496950Antiproliferative activity against human KBV1 cells overexpressing MDR1 after 72 hrs by Alamar blue assay in presence of zosuquidar2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
AID614420Growth inhibition of human SN12C cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1413007Antiproliferative activity against human U138MG cells after 24 hrs by MTS assay
AID1413019Inhibition of EG5 in human U138MG cells assessed as monopolar spindle formation at 200 uM after 24 hrs by Hoechst staining based immunofluorescence microscopic method
AID614356Growth inhibition of human MOLT4 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID300455Inhibition of microtubule-stimulated Eg5 ATPase activity expressed in Escherichia coli after 12 hrs2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
New chemical tools for investigating human mitotic kinesin Eg5.
AID1615138Antiproliferative activity against human HCT116 cells incubated for 72 hrs by MTT assay2019MedChemComm, Sep-01, Volume: 10, Issue:9
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
AID1494060Inhibition of human Cav1.2 expressed in HEK293 cells assessed as reduction in Ca2+ uptake at 100 uM measured as first 2 mins sampled at a frequency of one sample every second and the last 12 min at a frequency of one sample every 5 secs by fluo-3AM-based 2018European journal of medicinal chemistry, Jan-01, Volume: 143Biological activity of dihydropyrimidinone (DHPM) derivatives: A systematic review.
AID1615137Antiproliferative activity against human A549 cells incubated for 72 hrs by MTT assay2019MedChemComm, Sep-01, Volume: 10, Issue:9
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
AID344660Effect on cell cycle progression in human HCT116 cells assessed as increase in phospho-histone H3 by fluorescence microscopy2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
AID614408Growth inhibition of human SK-MEL-5 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1272854Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged KIFC3 ATPase activity at 15 uM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1413005Antiproliferative activity against human U138MG cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTS assay relative to control
AID1615140Cytotoxicity against human MSC assessed as reduction in cell viability incubated for 72 hrs by MTT assay2019MedChemComm, Sep-01, Volume: 10, Issue:9
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
AID496948Drug resistant ratio of EC50 for human KBV1 cells overexpressing MDR1 to EC50 for KB3-1 cells2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
AID1615142Inhibition of L-type calcium channel in Wistar rat aortic rings assessed as reduction in (-)-Bay K8644-induced contractions at 10'-4 M measured after 20 mins2019MedChemComm, Sep-01, Volume: 10, Issue:9
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
AID300454Inhibition of Eg5 ATPase activity expressed in Escherichia coli after 12 hrs2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
New chemical tools for investigating human mitotic kinesin Eg5.
AID1413006Antiproliferative activity against rat C6 cells assessed as reduction in cell viability at 100 uM after 24 hrs by MTS assay relative to control
AID1377424Induction of apoptosis in human HL-60(TB) cells assessed as late apoptotic cells at 0.294 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.39%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID1202218Cytotoxicity against human U138MG cells assessed as growth inhibition at 150 uM relative to control2015European journal of medicinal chemistry, May-05, Volume: 95Novel hybrid DHPM-fatty acids: synthesis and activity against glioma cell growth in vitro.
AID614419Growth inhibition of human Caki1 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614412Growth inhibition of human OVCAR3 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1377670Modulation of human alpha1beta2delta GABAA receptor expressed in Xenopus laevis oocytes assessed as increase in GABA-induced current at 1 mM at -60 mV holding potential by two-electrode voltage clamp electrophysiology method relative to control2017European journal of medicinal chemistry, Sep-29, Volume: 138Monastrol, a 3,4-dihydropyrimidin-2(1H)-thione, as structural scaffold for the development of modulators for GHB high-affinity binding sites and α
AID1377433Induction of apoptosis in human MOLT4 cells assessed as necrotic cells at 0.43 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.11%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID614369Growth inhibition of human HCT15 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1377399Growth inhibition of human MOLT4 cells incubated for 24 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID1272856Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged MKLP1 ATPase activity at 15 uM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID614472Cytotoxicity against human AGS cells after 48 hrs by SRB assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors.
AID512985Inhibition of recombinant Eg5-GFP in cell-free system assessed as Eg5 motility speed on microtubule at 25 uM by kymograph analysis in presence of 2 mM ATP (Rvb = 13.5+/-0.7 nm/s)2006Nature chemical biology, Sep, Volume: 2, Issue:9
Allosteric inhibition of kinesin-5 modulates its processive directional motility.
AID512990Inhibition of recombinant Eg5-GFP in cell-free system assessed as reduction in mean duration of Eg5-GFP-microtubule interaction at 100 uM by kymograph analysis2006Nature chemical biology, Sep, Volume: 2, Issue:9
Allosteric inhibition of kinesin-5 modulates its processive directional motility.
AID614360Growth inhibition of human EKVX cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1413436Cytotoxicity against rat C6 cells assessed as reduction in cell viability after 48 hrs by MTT assay2018MedChemComm, Aug-01, Volume: 9, Issue:8
Synthesis and antitumoral activity of novel analogues monastrol-fatty acids against glioma cells.
AID1377437Induction of apoptosis in human MOLT4 cells assessed as increase in apoptotic cells at 0.43 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry relative to control2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID1610645Cell cycle arrest in human SNB75 cells assessed as accumulation in preG1 phase at 2 uM incubated for 24 hrs by propidium iodide based flow cytometry (Rvb = 1.85 %)
AID614397Growth inhibition of human SF268 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614355Growth inhibition of human K562 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1377408Cell cycle arrest in human HL-60(TB) cells assessed as accumulation at G2/M phase at 0.294 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 7.29%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID1413740Antiproliferative activity against human NCI/ADR-RES cells at 25 uM after 48 hrs by sulforhodamine B assay2018MedChemComm, Sep-01, Volume: 9, Issue:9
Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity.
AID1292206Antileishmanial activity against Leishmania major promastigotes after 72 hrs by Neubauer chamber counting2016European journal of medicinal chemistry, Jun-10, Volume: 115Structure based medicinal chemistry-driven strategy to design substituted dihydropyrimidines as potential antileishmanial agents.
AID614396Growth inhibition of human SW620 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1377416Cell cycle arrest in human MOLT4 cells assessed as accumulation at G2/M phase at 0.43 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 4.35%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID614398Growth inhibition of human SF295 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1202217Cytotoxicity against rat C6 cells assessed as growth inhibition at 150 uM relative to control2015European journal of medicinal chemistry, May-05, Volume: 95Novel hybrid DHPM-fatty acids: synthesis and activity against glioma cell growth in vitro.
AID614400Growth inhibition of human SNB19 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1360879Cytotoxicity against mouse McCoy cells assessed as decrease in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Novel pyrimidinic selenourea induces DNA damage, cell cycle arrest, and apoptosis in human breast carcinoma.
AID1377671Agonist activity at human alpha1beta2delta GABAA receptor expressed in Xenopus laevis oocytes assessed as increase in current amplitude at 1 mM at -60 mV holding potential by two-electrode voltage clamp electrophysiology method2017European journal of medicinal chemistry, Sep-29, Volume: 138Monastrol, a 3,4-dihydropyrimidin-2(1H)-thione, as structural scaffold for the development of modulators for GHB high-affinity binding sites and α
AID496942Antiproliferative activity against human hTERT-HME1 cells after 72 hrs by Alamar blue assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
AID740791Inhibition of Eg5 (unknown origin)2013European journal of medicinal chemistry, Apr, Volume: 62Advances in the discovery of kinesin spindle protein (Eg5) inhibitors as antitumor agents.
AID1377423Induction of apoptosis in human HL-60(TB) cells assessed as early apoptotic cells at 0.294 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.84%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID1413008Antiproliferative activity against rat C6 cells after 24 hrs by MTS assay
AID608381Inhibition of HsEg52011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Synthesis and biological evaluation of conformationally flexible as well as restricted dimers of monastrol and related dihydropyrimidones.
AID1272857Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged Kif5B ATPase activity at 15 uM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1360878Cytotoxicity against human HeLa cells assessed as decrease in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Novel pyrimidinic selenourea induces DNA damage, cell cycle arrest, and apoptosis in human breast carcinoma.
AID614354Growth inhibition of human HL-60(TB) cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1377674Modulation of human alpha1beta2gamma2S GABAA receptor expressed in Xenopus laevis oocytes assessed as increase in GABA-induced current at 1 mM at -60 mV holding potential by two-electrode voltage clamp electrophysiology method2017European journal of medicinal chemistry, Sep-29, Volume: 138Monastrol, a 3,4-dihydropyrimidin-2(1H)-thione, as structural scaffold for the development of modulators for GHB high-affinity binding sites and α
AID1413739Antiproliferative activity against human MCF7 cells at 25 uM after 48 hrs by sulforhodamine B assay2018MedChemComm, Sep-01, Volume: 9, Issue:9
Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity.
AID614358Growth inhibition of human SR cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID608362Cytotoxicity against human MCF7 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Synthesis and biological evaluation of conformationally flexible as well as restricted dimers of monastrol and related dihydropyrimidones.
AID614422Growth inhibition of human UO31 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614416Growth inhibition of human SKOV3 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID537126Cytotoxicity against human HCT116 cells after 72 hrs by MTT assay2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Design, synthesis and bioevaluation of dihydropyrazolo[3,4-b]pyridine and benzo[4,5]imidazo[1,2-a]pyrimidine compounds as dual KSP and Aurora-A kinase inhibitors for anti-cancer agents.
AID614470Inhibition of human ATPase activity KSP expressed in Escherichia coli after 30 mins by spectrophotometric analysis2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors.
AID1360883Selectivity index, ratio of IC50 for mouse McCoy cells to IC50 for human HeLa cells2018European journal of medicinal chemistry, Jul-15, Volume: 155Novel pyrimidinic selenourea induces DNA damage, cell cycle arrest, and apoptosis in human breast carcinoma.
AID614406Growth inhibition of human SK-MEL-2 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID300459Inhibition of Eg5 ATPase activity expressed in HeLa cells after 12 hrs2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
New chemical tools for investigating human mitotic kinesin Eg5.
AID1377407Cell cycle arrest in human HL-60(TB) cells assessed as accumulation at G0/G1 phase at 0.294 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 68.43%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID614394Growth inhibition of human HT-29 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614410Growth inhibition of human UACC62 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1413742Antiproliferative activity against human HT-29 cells at 25 uM after 48 hrs by sulforhodamine B assay2018MedChemComm, Sep-01, Volume: 9, Issue:9
Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity.
AID537125Inhibition of human purified recombinant aurora-A kinase2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Design, synthesis and bioevaluation of dihydropyrazolo[3,4-b]pyridine and benzo[4,5]imidazo[1,2-a]pyrimidine compounds as dual KSP and Aurora-A kinase inhibitors for anti-cancer agents.
AID614418Growth inhibition of human ACHN cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614362Growth inhibition of human NCI-H226 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID608376Binding affinity to calf thymus DNA assessed as change in melting temperature at compound to DNA ratio of of 1:5 after 18 hrs at pH 72011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Synthesis and biological evaluation of conformationally flexible as well as restricted dimers of monastrol and related dihydropyrimidones.
AID1413011Cell cycle arrest in rat C6 cells assessed as accumulation at G2/M phase at 100 uM after 24 hrs by propidium iodide staining based flow cytometry
AID1610650Induction of apoptosis in human MDA-MB-435 cells assessed as active caspase 9 level incubated for 2 hrs by ELISA (Rvb = 1 No_unit)
AID614403Growth inhibition of human LOXIMVI cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614363Growth inhibition of human NCI-H23 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614407Growth inhibition of human SK-MEL-28 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1377409Cell cycle arrest in human HL-60(TB) cells assessed as accumulation at S phase at 0.294 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 22.84%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID496946Antiproliferative activity against human KB3-1 cells after 72 hrs by Alamar blue assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
AID1413009Cell cycle arrest in human U138MG cells assessed as accumulation at G2/M phase at 200 uM after 24 hrs by propidium iodide staining based flow cytometry relative to control
AID614361Growth inhibition of human HOP62 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID521220Inhibition of neurosphere proliferation of mouse neural precursor cells by MTT assay2007Nature chemical biology, May, Volume: 3, Issue:5
Chemical genetics reveals a complex functional ground state of neural stem cells.
AID1615136Antiproliferative activity against human MM1S cells incubated for 72 hrs by MTT assay2019MedChemComm, Sep-01, Volume: 10, Issue:9
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
AID512987Inhibition of recombinant Eg5-GFP in cell-free system assessed as Eg5 motility speed on microtubule at 25 uM by mean square displacement analysis in presence of 2 mM ATP (Rvb = 799+/-nm'2/s)2006Nature chemical biology, Sep, Volume: 2, Issue:9
Allosteric inhibition of kinesin-5 modulates its processive directional motility.
AID1615132Vasodilating activity in Wistar rat aortic rings assessed as reduction in phenylephrine-induced contractions relative to control2019MedChemComm, Sep-01, Volume: 10, Issue:9
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
AID512989Inhibition of recombinant Eg5-GFP in cell-free system assessed as reduction of Eg5 motility speed on microtubule at 100 uM by kymograph analysis2006Nature chemical biology, Sep, Volume: 2, Issue:9
Allosteric inhibition of kinesin-5 modulates its processive directional motility.
AID1413016Induction of necrosis in human U138MG cells at 200 uM after 48 hrs by Annexin V/propidium iodide staining based flow cytometry
AID1413014Induction of apoptosis in human U138MG cells at 200 uM after 48 hrs by Annexin V/propidium iodide staining based flow cytometry
AID608366Cytotoxicity against human A549 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Synthesis and biological evaluation of conformationally flexible as well as restricted dimers of monastrol and related dihydropyrimidones.
AID1740949Substrate activity at recombinant human C-terminal His-tagged NQO1 (1 to 274 residues) expressed in Escherichia coli assessed as metabolic rate by measuring NADPH oxidation per micromol protein at 10 mmol/L measured at 5 secs interval for 1 min by UV-Visi2020European journal of medicinal chemistry, Oct-01, Volume: 203Synthesis and biological evaluation of β-lapachone-monastrol hybrids as potential anticancer agents.
AID1413017Induction of apoptosis in rat C6 cells at 100 uM after 48 hrs by Annexin V/propidium iodide staining based flow cytometry
AID344659Effect on cell cycle progression in human HCT116 cells assessed as mitotic arrest measured by doubling DNA content by fluorescence microscopy2008Bioorganic & medicinal chemistry letters, Oct-15, Volume: 18, Issue:20
Design and synthesis of 2-amino-pyrazolopyridines as Polo-like kinase 1 inhibitors.
AID1413743Antiproliferative activity against human UACC62 cells at 25 uM after 48 hrs by sulforhodamine B assay2018MedChemComm, Sep-01, Volume: 9, Issue:9
Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity.
AID1413741Antiproliferative activity against human 786-0 cells at 25 uM after 48 hrs by sulforhodamine B assay2018MedChemComm, Sep-01, Volume: 9, Issue:9
Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity.
AID1284140Inhibition of GFP-tagged Xenopus laevis kinesin-5 microtubule gliding velocity by fluorescence assay2016European journal of medicinal chemistry, Apr-13, Volume: 112The natural diterpene tonantzitlolone A and its synthetic enantiomer inhibit cell proliferation and kinesin-5 function.
AID1377673Modulation of human alpha1beta2 GABAA receptor expressed in Xenopus laevis oocytes assessed as increase in GABA-induced current at 1 mM at -60 mV holding potential by two-electrode voltage clamp electrophysiology method2017European journal of medicinal chemistry, Sep-29, Volume: 138Monastrol, a 3,4-dihydropyrimidin-2(1H)-thione, as structural scaffold for the development of modulators for GHB high-affinity binding sites and α
AID614421Growth inhibition of human TK10 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1610646Induction of apoptosis in human SNB75 cells assessed as early apoptotic cells at 2 uM incubated for 24 hrs by annexin V FITC and propidium iodide based flow cytometry (Rvb = 0.82 %)
AID614415Growth inhibition of human OVCAR8 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID496941Antiproliferative activity against human HCT116 cells after 72 hrs by Alamar blue assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
AID1413744Antiproliferative activity against human PC3 cells at 25 uM after 48 hrs by sulforhodamine B assay2018MedChemComm, Sep-01, Volume: 9, Issue:9
Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity.
AID614417Growth inhibition of human 786-0 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1610647Induction of apoptosis in human SNB75 cells assessed as late apoptotic cells at 2 uM incubated for 24 hrs by annexin V FITC and propidium iodide based flow cytometry (Rvb = 0.59 %)
AID1413021Inhibition of EG5 in rat C6 cells assessed as monopolar spindle formation at 100 uM after 24 hrs by Hoechst staining based immunofluorescence microscopic method
AID1272851Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged CENP-E ATPase activity at 15 uM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1377669Modulation of [3H]NCS-382 binding to alpha4betadelta GABAA receptor in rat cortical membranes assessed as [3H]NCS-382 binding at 100 uM after 1 hr by TopCount scintillation counting method relative to control2017European journal of medicinal chemistry, Sep-29, Volume: 138Monastrol, a 3,4-dihydropyrimidin-2(1H)-thione, as structural scaffold for the development of modulators for GHB high-affinity binding sites and α
AID614401Growth inhibition of human SNB75 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614413Growth inhibition of human OVCAR4 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1377668Modulation of [3H]NCS-382 binding to alpha4betadelta GABAA receptor in rat cortical membranes after 1 hr by TopCount scintillation counting method2017European journal of medicinal chemistry, Sep-29, Volume: 138Monastrol, a 3,4-dihydropyrimidin-2(1H)-thione, as structural scaffold for the development of modulators for GHB high-affinity binding sites and α
AID1377430Induction of apoptosis in human MOLT4 cells assessed as live cells at 0.43 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 99.12%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID614364Growth inhibition of human NCI-H322M cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614399Growth inhibition of human SF539 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1272855Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged KIF3C ATPase activity at 15 uM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1610644Cell cycle arrest in human SNB75 cells assessed as accumulation in G2/M phase at 2 uM incubated for 24 hrs by propidium iodide based flow cytometry (Rvb = 10.46 %)
AID614368Growth inhibition of human HCT116 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1610651Inhibition of recombinant human His-tagged Eg5 (1 to 368 residues) assessed as reduction in ATPase activity by Bradford reagent based assay
AID1272853Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged Eg5 ATPase activity at 15 uM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1413437Antiproliferative activity against rat C6 cells at 5 to 50 uM after 48 hrs by Neubauer chamber method2018MedChemComm, Aug-01, Volume: 9, Issue:8
Synthesis and antitumoral activity of novel analogues monastrol-fatty acids against glioma cells.
AID1377431Induction of apoptosis in human MOLT4 cells assessed as early apoptotic cells at 0.43 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.53%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID300461Cell cycle arrest in human HeLa cells assessed as 4N DNA content at 100 uM after 24 hrs2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
New chemical tools for investigating human mitotic kinesin Eg5.
AID614366Growth inhibition of human COLO205 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1377414Cell cycle arrest in human MOLT4 cells assessed as accumulation of apoptotic cells in pre-G phase at 0.43 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 0.88%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID1610643Cell cycle arrest in human SNB75 cells assessed as accumulation in S phase at 2 uM incubated for 24 hrs by propidium iodide based flow cytometry (Rvb = 33.92 %)
AID614367Growth inhibition of human HCC2998 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID496949Antiproliferative activity against human KB3-1 cells after 72 hrs by Alamar blue assay in presence of zosuquidar2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
AID1377406Cell cycle arrest in human HL-60(TB) cells assessed as accumulation of apoptotic cells in pre-G phase at 0.294 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 1.44%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID614402Growth inhibition of human U251 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614359Growth inhibition of human A549 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614404Growth inhibition of human MALME-3M cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID723809Inhibition of Eg5 (unknown origin)2013European journal of medicinal chemistry, Feb, Volume: 60Discovery of coumarin-monastrol hybrid as potential antibreast tumor-specific agent.
AID1615131Vasodilating activity in Wistar rat aortic rings assessed as reduction in phenylephrine-induced contractions2019MedChemComm, Sep-01, Volume: 10, Issue:9
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
AID1272852Inhibition of porcine brain microtubule-stimulated human recombinant GST-tagged Kif4A ATPase activity at 15 uM by microplate reader in presence of Mg2+ ATP relative to control2016Bioorganic & medicinal chemistry, Feb-15, Volume: 24, Issue:4
New MKLP-2 inhibitors in the paprotrain series: Design, synthesis and biological evaluations.
AID1377422Induction of apoptosis in human HL-60(TB) cells assessed as live cells at 0.294 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 98.57%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID537124Inhibition of human full-length Eg5 ATPase activity expressed in Escherichia coli assessed as release of inorganic phosphate after 30 mins2010Bioorganic & medicinal chemistry, Nov-15, Volume: 18, Issue:22
Design, synthesis and bioevaluation of dihydropyrazolo[3,4-b]pyridine and benzo[4,5]imidazo[1,2-a]pyrimidine compounds as dual KSP and Aurora-A kinase inhibitors for anti-cancer agents.
AID614471Cytotoxicity against human A549 cells after 48 hrs by SRB assay2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
De novo design, synthesis and biological evaluation of 1,4-dihydroquinolin-4-ones and 1,2,3,4-tetrahydroquinazolin-4-ones as potent kinesin spindle protein (KSP) inhibitors.
AID1377425Induction of apoptosis in human HL-60(TB) cells assessed as necrotic cells at 0.294 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.2%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID614405Growth inhibition of human M14 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1413023Toxicity in Caenorhabditis elegans N2 L1 larva assessed as mortality incubated for 30 mins on rotator and measured after 24 hrs
AID496944Antiproliferative activity against human K562 cells after 72 hrs by Alamar blue assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
AID1413745Antiproliferative activity against human OVCAR3 cells at 25 uM after 48 hrs by sulforhodamine B assay2018MedChemComm, Sep-01, Volume: 9, Issue:9
Synthesis of novel perillyl-dihydropyrimidinone hybrids designed for antiproliferative activity.
AID608365Cytotoxicity against human A431 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Synthesis and biological evaluation of conformationally flexible as well as restricted dimers of monastrol and related dihydropyrimidones.
AID1610648Induction of apoptosis in human SNB75 cells assessed as necrosis at 2 uM incubated for 24 hrs by annexin V FITC and propidium iodide based flow cytometry (Rvb = 0.44 %)
AID1610641Inhibition of kinesin (unknown origin) assessed as reduction in ATPase activity using microtubule as substrate measured for 5 to mins
AID496943Antiproliferative activity against human BxPC3 cells after 72 hrs by Alamar blue assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
AID608363Cytotoxicity against human COLO205 cells after 48 hrs by MTT assay2011European journal of medicinal chemistry, Aug, Volume: 46, Issue:8
Synthesis and biological evaluation of conformationally flexible as well as restricted dimers of monastrol and related dihydropyrimidones.
AID300456Induction of monoastral spindles in HeLa cells at 100 uM after 7 hrs2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
New chemical tools for investigating human mitotic kinesin Eg5.
AID1615139Antiproliferative activity against human MCF7 cells incubated for 72 hrs by MTT assay2019MedChemComm, Sep-01, Volume: 10, Issue:9
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
AID614414Growth inhibition of human OVCAR5 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1615135Vasodilating activity in Wistar rat aortic rings assessed as reduction in phenylephrine-induced contractions in presence of Cacl2 in calcium free Krebs medium incubated for 1 hr relative to control2019MedChemComm, Sep-01, Volume: 10, Issue:9
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
AID512986Inhibition of recombinant Eg5-GFP in cell-free system assessed as Eg5 motility speed on microtubule at 100 uM by kymograph analysis in presence of 2 mM ATP (Rvb = 13.5+/-0.7 nm/s)2006Nature chemical biology, Sep, Volume: 2, Issue:9
Allosteric inhibition of kinesin-5 modulates its processive directional motility.
AID1360882Selectivity index, ratio of IC50 for mouse McCoy cells to IC50 for human MCF7 cells2018European journal of medicinal chemistry, Jul-15, Volume: 155Novel pyrimidinic selenourea induces DNA damage, cell cycle arrest, and apoptosis in human breast carcinoma.
AID300457Induction of monoastral spindles in HeLa cells at 50 uM after 7 hrs2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
New chemical tools for investigating human mitotic kinesin Eg5.
AID614409Growth inhibition of human UACC257 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1377435Induction of apoptosis in human HL-60(TB) cells assessed as increase in apoptotic cells at 0.294 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry relative to control2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID1610649Induction of apoptosis in human MDA-MB-435 cells assessed as active caspase 3 level incubated for 2 hrs by ELISA (Rvb = 1 No_unit)
AID1377398Growth inhibition of human HL-60(TB) cells incubated for 24 hrs by MTT assay2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID496947Antiproliferative activity against human KBV1 cells overexpressing MDR1 after 72 hrs by Alamar blue assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
AID614353Growth inhibition of human CCRF-CEM cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1610642Cell cycle arrest in human SNB75 cells assessed as accumulation in G0/G1 phase at 2 uM incubated for 24 hrs by propidium iodide based flow cytometry (Rvb = 55.62 %)
AID614411Growth inhibition of human IGROV1 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID614365Growth inhibition of human NCI-H522 cells2011Bioorganic & medicinal chemistry, Sep-15, Volume: 19, Issue:18
Synthesis and characterization of tritylthioethanamine derivatives with potent KSP inhibitory activity.
AID1377675Modulation of human alpha1beta2delta GABAA receptor expressed in Xenopus laevis oocytes assessed as increase in GABA-induced current by measuring rebound current at -60 mV holding potential measured after termination of compound application by two-electro2017European journal of medicinal chemistry, Sep-29, Volume: 138Monastrol, a 3,4-dihydropyrimidin-2(1H)-thione, as structural scaffold for the development of modulators for GHB high-affinity binding sites and α
AID1377432Induction of apoptosis in human MOLT4 cells assessed as late apoptotic cells at 0.43 uM after 24 hrs by Annexin V-FITC/propidium iodide staining based flow cytometry (Rvb = 0.24%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID1377417Cell cycle arrest in human MOLT4 cells assessed as accumulation at S phase at 0.43 uM after 24 hrs by propidium iodide staining based flow cytometry (Rvb = 20.55%)2017European journal of medicinal chemistry, Sep-29, Volume: 138Design, synthesis and anticancer activity of new monastrol analogues bearing 1,3,4-oxadiazole moiety.
AID496945Antiproliferative activity against human NCI-H1299 cells after 72 hrs by Alamar blue assay2010Journal of medicinal chemistry, Aug-12, Volume: 53, Issue:15
Structural basis for inhibition of Eg5 by dihydropyrimidines: stereoselectivity of antimitotic inhibitors enastron, dimethylenastron and fluorastrol.
AID1656399Inhibition of Eg5 in Schizosaccharomyces pombe TY27 overexpressing GFP-HSET assessed as growth restoring activity incubated for 3 days by agar plate-based method2020Bioorganic & medicinal chemistry, 01-01, Volume: 28, Issue:1
Kolavenic acid analog restores growth in HSET-overproducing fission yeast cells and multipolar mitosis in MDA-MB-231 human cells.
AID1615133Vasodilating activity in Wistar rat aortic rings assessed as reduction in KCl-induced contractions2019MedChemComm, Sep-01, Volume: 10, Issue:9
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
AID1174089Inhibition of recombinant N-terminal His6-tagged KIFC1 (Q305-K673 aa) (unknown origin) expressed in Escherichia coli BL21 (DE3) by malachite green assay2014Journal of medicinal chemistry, Dec-11, Volume: 57, Issue:23
Discovery of potent KIFC1 inhibitors using a method of integrated high-throughput synthesis and screening.
AID1360877Cytotoxicity against human MCF7 cells assessed as decrease in cell viability after 72 hrs by MTT assay2018European journal of medicinal chemistry, Jul-15, Volume: 155Novel pyrimidinic selenourea induces DNA damage, cell cycle arrest, and apoptosis in human breast carcinoma.
AID300458Induction of monoastral spindles in HeLa cells after 7 hrs2007Bioorganic & medicinal chemistry, Oct-01, Volume: 15, Issue:19
New chemical tools for investigating human mitotic kinesin Eg5.
AID1615134Vasodilating activity in Wistar rat aortic rings assessed as reduction in KCl-induced contractions relative to control2019MedChemComm, Sep-01, Volume: 10, Issue:9
Dihydropyrimidine-2-thiones as Eg5 inhibitors and L-type calcium channel blockers: potential antitumour dual agents.
AID1347125qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347128qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347117qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347113qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347108qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347129qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347083qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: Viability assay - alamar blue signal for LASV Primary Screen2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347116qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347086qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lymphocytic Choriomeningitis Arenaviruses (LCMV): LCMV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347122qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347121qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347098qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-SH cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347110qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for A673 cells)2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347089qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346986P-glycoprotein substrates identified in KB-3-1 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347093qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347104qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347092qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for A673 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347097qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1296008Cytotoxic Profiling of Annotated Libraries Using Quantitative High-Throughput Screening2020SLAS discovery : advancing life sciences R & D, 01, Volume: 25, Issue:1
Cytotoxic Profiling of Annotated and Diverse Chemical Libraries Using Quantitative High-Throughput Screening.
AID1347100qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for LAN-5 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347101qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347118qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for TC32 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347106qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for control Hh wild type fibroblast cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1346987P-glycoprotein substrates identified in KB-8-5-11 adenocarcinoma cell line, qHTS therapeutic library screen2019Molecular pharmacology, 11, Volume: 96, Issue:5
A High-Throughput Screen of a Library of Therapeutics Identifies Cytotoxic Substrates of P-glycoprotein.
AID1347095qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347115qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB-EBc1 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347099qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347091qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for SJ-GBM2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347096qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for U-2 OS cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347124qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for RD cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347105qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347112qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for BT-12 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1508630Primary qHTS for small molecule stabilizers of the endoplasmic reticulum resident proteome: Secreted ER Calcium Modulated Protein (SERCaMP) assay2021Cell reports, 04-27, Volume: 35, Issue:4
A target-agnostic screen identifies approved drugs to stabilize the endoplasmic reticulum-resident proteome.
AID1347103qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for OHS-50 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347082qHTS for Inhibitors of the Functional Ribonucleoprotein Complex (vRNP) of Lassa (LASV) Arenavirus: LASV Primary Screen - GLuc reporter signal2020Antiviral research, 01, Volume: 173A cell-based, infectious-free, platform to identify inhibitors of lassa virus ribonucleoprotein (vRNP) activity.
AID1347123qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh41 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347126qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347094qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for BT-37 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347111qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for SK-N-MC cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347127qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for Saos-2 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347114qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347107qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh30 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347090qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for DAOY cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347109qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for NB1643 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1347102qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Primary screen for Rh18 cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID1745845Primary qHTS for Inhibitors of ATXN expression
AID1347154Primary screen GU AMC qHTS for Zika virus inhibitors2020Proceedings of the National Academy of Sciences of the United States of America, 12-08, Volume: 117, Issue:49
Therapeutic candidates for the Zika virus identified by a high-throughput screen for Zika protease inhibitors.
AID1347119qHTS of pediatric cancer cell lines to identify multiple opportunities for drug repurposing: Confirmatory screen for MG 63 (6-TG R) cells2018Oncotarget, Jan-12, Volume: 9, Issue:4
Quantitative high-throughput phenotypic screening of pediatric cancer cell lines identifies multiple opportunities for drug repurposing.
AID588519A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities2011Antiviral research, Sep, Volume: 91, Issue:3
High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors.
AID1347411qHTS to identify inhibitors of the type 1 interferon - major histocompatibility complex class I in skeletal muscle: primary screen against the NCATS Mechanism Interrogation Plate v5.0 (MIPE) Libary2020ACS chemical biology, 07-17, Volume: 15, Issue:7
High-Throughput Screening to Identify Inhibitors of the Type I Interferon-Major Histocompatibility Complex Class I Pathway in Skeletal Muscle.
AID540299A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis2010Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21
Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
AID1801532Urease Inhibition Assay from Article 10.1016/j.bioorg.2015.12.007: \\Dihydropyrimidine based hydrazine dihydrochloride derivatives as potent urease inhibitors.\\2016Bioorganic chemistry, Feb, Volume: 64Dihydropyrimidine based hydrazine dihydrochloride derivatives as potent urease inhibitors.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (166)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (1.20)18.2507
2000's67 (40.36)29.6817
2010's81 (48.80)24.3611
2020's16 (9.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 36.84

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be strong demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index36.84 (24.57)
Research Supply Index5.12 (2.92)
Research Growth Index5.91 (4.65)
Search Engine Demand Index48.73 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (36.84)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews6 (3.59%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other161 (96.41%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]